Skip to Content

Afatinib Pregnancy and Breastfeeding Warnings

Afatinib is also known as: Gilotrif

Medically reviewed on November 13, 2017.

Afatinib Pregnancy Warnings

FDA pregnancy category: D

Use of afatinib is not recommended unless the benefit outweighs the risk to the developing fetus. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.

-Advise females of reproductive potential to use highly effective contraception during treatment, and for at least 2 weeks after the last dose of afatinib.
-Advise patients to contact their healthcare provider if they become pregnant, or if pregnancy is suspected, while taking afatinib.

See references

Afatinib Breastfeeding Warnings

A decision should be made to discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother.

Excreted into human milk: Unknown
Excreted into animal milk: Yes

The effects in the nursing infant are unknown.

See references

References for pregnancy information

  1. "Product Information. Gilotrif (afatinib)." Boehringer Ingelheim, Ridgefield, CT.

References for breastfeeding information

  1. "Product Information. Gilotrif (afatinib)." Boehringer Ingelheim, Ridgefield, CT.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.